These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 38888921)

  • 21. Availability of Specific Programs and Medications for Addiction Treatment to Vulnerable Populations: Results from the Addiction Treatment Locator, Assessment, and Standards (ATLAS) Survey.
    Oldfield BJ; Chen K; Joudrey PJ; Biegacki ET; Fiellin DA
    J Addict Med; 2023 Jul-Aug 01; 17(4):477-480. PubMed ID: 37579115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expanding access to Medication for Opioid Use Disorder (MOUD) in jails: A comprehensive program evaluation.
    Pourtaher E; Gelberg KH; Fallico M; Ellendon N; Li S
    J Subst Use Addict Treat; 2024 Jun; 161():209248. PubMed ID: 38081540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use.
    Xu KY; Mintz CM; Presnall N; Bierut LJ; Grucza RA
    JAMA Netw Open; 2022 May; 5(5):e2211363. PubMed ID: 35536575
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dialing for doctors: Secret shopper study of Arizona methadone and buprenorphine providers, 2022.
    Meyerson BE; Treiber D; Brady BR; Newgass K; Bondurant K; Bentele KG; Samorano S; Arredondo C; Stavros N
    J Subst Use Addict Treat; 2024 May; 160():209306. PubMed ID: 38296033
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between availability of medications for opioid use disorder in specialty treatment and use of medications among patients: A state-level trends analysis.
    Solomon KT; Bandara S; Reynolds IS; Krawczyk N; Saloner B; Stuart E; Connolly E
    J Subst Abuse Treat; 2022 Jan; 132():108424. PubMed ID: 34144299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characteristics of US Counties With High Opioid Overdose Mortality and Low Capacity to Deliver Medications for Opioid Use Disorder.
    Haffajee RL; Lin LA; Bohnert ASB; Goldstick JE
    JAMA Netw Open; 2019 Jun; 2(6):e196373. PubMed ID: 31251376
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.
    Wakeman SE; Larochelle MR; Ameli O; Chaisson CE; McPheeters JT; Crown WH; Azocar F; Sanghavi DM
    JAMA Netw Open; 2020 Feb; 3(2):e1920622. PubMed ID: 32022884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Payment-related barriers to medications for opioid use disorder: A critical review of the literature and real-world application.
    Bowser D; Bohler R; Davis MT; Hodgkin D; Horgan C
    J Subst Use Addict Treat; 2024 Oct; 165():209441. PubMed ID: 38906417
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Medication Treatment of Active Opioid Use Disorder in Veterans With Cirrhosis.
    Rogal S; Youk A; Agbalajobi O; Zhang H; Gellad W; Fine MJ; Belperio P; Morgan T; Good CB; Kraemer K
    Am J Gastroenterol; 2021 Jul; 116(7):1406-1413. PubMed ID: 33811202
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Associations Between Copays, Coverage Limits for Opioid Use Disorder Medications, and Prescribing in Medicaid, 2018.
    Barenie RE; Kesselheim AS; Tsacogianis T; Fischer MA
    Med Care; 2021 Mar; 59(3):266-272. PubMed ID: 33560766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treating opioid use disorder in veterans with co-occurring substance use: a qualitative study with buprenorphine providers in primary care, mental health, and pain settings.
    Frost MC; Soyer EM; Achtmeyer CE; Hawkins EJ; Glass JE; Hallgren KA; Williams EC
    Addict Sci Clin Pract; 2023 May; 18(1):26. PubMed ID: 37143162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Opioid use disorder incidence and treatment among incarcerated pregnant women in the United States: results from a national surveillance study.
    Sufrin C; Sutherland L; Beal L; Terplan M; Latkin C; Clarke JG
    Addiction; 2020 Nov; 115(11):2057-2065. PubMed ID: 32141128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Consumer access to buprenorphine and methadone in certified community behavioral health centers: A secret shopper study.
    Presnall NJ; Butler GC; Grucza RA
    J Subst Abuse Treat; 2022 Aug; 139():108788. PubMed ID: 35534359
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population-based estimates of geographic accessibility of medication for opioid use disorder by substance use disorder treatment facilities from 2014 to 2020.
    Cantor J; Powell D; Kofner A; Stein BD
    Drug Alcohol Depend; 2021 Dec; 229(Pt A):109107. PubMed ID: 34656034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Access to Medications for Opioid Use Disorder and Associated Factors Among Adolescents and Young Adults: A Systematic Review.
    Pilarinos A; Bromberg DJ; Karamouzian M
    JAMA Pediatr; 2022 Mar; 176(3):304-311. PubMed ID: 34870707
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The estimated impact of state-level support for expanded delivery of substance use disorder treatment during the COVID-19 pandemic.
    Nesoff ED; Marziali ME; Martins SS
    Addiction; 2022 Jun; 117(6):1781-1786. PubMed ID: 34873783
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of polysubstance use disorder with treatment quality among Medicaid beneficiaries with opioid use disorder.
    Smart R; Kim JY; Kennedy S; Tang L; Allen L; Crane D; Mack A; Mohamoud S; Pauly N; Perez R; Donohue J
    J Subst Abuse Treat; 2023 Jan; 144():108921. PubMed ID: 36327615
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outpatient follow-up and use of medications for opioid use disorder after residential treatment among Medicaid enrollees in 10 states.
    ; Cole ES; Allen L; Austin A; Barnes A; Chang CH; Clark S; Crane D; Cunningham P; Fry CE; Gordon AJ; Hammerslag L; Idala D; Kennedy S; Kim JY; Krishnan S; Lanier P; Mahakalanda S; Mauk R; McDuffie MJ; Mohamoud S; Talbert J; Tang L; Zivin K; Donohue JM
    Drug Alcohol Depend; 2022 Dec; 241():109670. PubMed ID: 36332591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Associations Between Inpatient Induction on Medications for Opioid Use Disorder and Postdischarge Medications for Opioid Use Disorder Adherence, Overdose, and Service Use.
    Noam KR; Schmutte TJ; Pirard S; Bourdon C; Langless D; Plant R
    J Addict Med; 2023 May-Jun 01; 17(3):e199-e201. PubMed ID: 37267183
    [TBL] [Abstract][Full Text] [Related]  

  • 40. County-level sociodemographic differences in availability of two medications for opioid use disorder: United States, 2019.
    Corry B; Underwood N; Cremer LJ; Rooks-Peck CR; Jones C
    Drug Alcohol Depend; 2022 Jul; 236():109495. PubMed ID: 35605533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.